The epithelial-mesenchymal transition (EMT) is an important process in the progression of cancer. However, its occurrence and mechanism of regulation are not fully understood. We propose a regulatory pathway in which spermatogenic leucine zipper 1 (SPZ1) promotes EMT through its transactivating ability in increasing TWIST1 expression. We compared the expression of SPZ1 and TWIST1 in specimens of hepatocarcinoma cells (HCCs) and non-HCCs. Expression of SPZ1 exhibited a tumor-specific expression pattern and a high correlation with patients' survival time, tumor size, tumor number and progression stage. Moreover, forced expression and knockdown of SPZ1 in hepatoma cells showed that SPZ1 was able to regulate the cellular proliferation, invasion, and tumorigenic activity in a TWIST1-dependent manner in vitro and in vivo. These data demonstrate that SPZ1, a newly dscribed molecule, transactivates TWIST1 promoters, and that this SPZ1-TWIST axis mediates EMT signaling and exerts significant regulatory effects on tumor oncogenesis.
INTRODUCTION
Despite the identification of potential oncogenic drivers and their roles as master regulators of cancer initiation, the underlying mechanisms of tumorigenesis and metastasis remain unclear. 1, 2 TWIST1, a basic helix-loop-helix (bHLH) transcription factor, was originally identified as a mesoderm-inducing factor in Drosophila, 3, 4 and is now known as a principal inducer of the epithelial-mesenchymal transition (EMT) in human mammary epithelial cells 5 and other cancers. [6] [7] [8] Increased expression of TWIST1 promotes EMT by regulating cell motility, invasive activity and enhances features of cancer stem cells through controlling gene expression of downstream genes. 9, 10 A unique functuion of TWIST1 is to repress the transcription of E-cadherin directly via ciselements in the E-cadherin promoter, 11 and the expression of p53 indirectly via p14
Arf and the mouse double minute 2 homolog 12 or p300/CBP 8 or another mechanism. 13 However, the molecular pathways through which TWIST1 and the downstream events are regulated in tumor metastasis remain undefined. 5 Spermatogenic bHLH transcription factor Zip 1 (SPZ1) is expressed primarily during embryonic development stages, including those in stem cells and early gastrulation stages, but it shows a testis-specific expression in germline and somatic cells (Sertoli and Leydig cells) in the adult stage. 14, 15 Mitogen-activated protein kinase signaling promotes SPZ1 expression and activation by phosphorylation, which results in SPZ1 translocation into the nucleus and activation of downstream gene expression such as the proliferating cell nuclear antigen. 16 The DNA-binding elements of SPZ1 on the promoters have been found in its downstream genes, which contained E-boxes and G-boxes. 16 Functionally, ectopic SPZ1 promotes cell cycle progression and proliferation, and leads to tumor formation in cells and transgenic mice, including the formation of liver tumors. 15, 16 Overexpression of SPZ1 is detected in many human tumor tissues, but the detailed mechanisms of tumorigenesis and clinical outcomes of SPZ1 overexpression remain to be clarified.
We show here that SPZ1 activates TWIST1 expression and then promotes tumorigenesis in vitro and in vivo. These results suggest that SPZ1 is an important oncogene that is involved in the regulation of tumor initiation and cell plasticity in the tumorigenic microenvironment.
RESULTS

SPZ1
showed a tumor-specific expression pattern and its expression correlated with HCC clinical outcome Forced expression of SPZ1 promotes the cell growth and tumorigenicity in immortalized cells and transgenic mice. remain unclear. To this end, analysis of the expression patterns of SPZ1 in various tissue samples showed that the SPZ1 mRNA expression in HCC samples was significantly upregulated as compared with that in patients without HCC (Figure 1a ; Po 0.001, Mann-Whitney test). Analysis of the expression patterns in dichotomized groups according to the level of SPZ1 expression indicated that the top 30th percentile (n = 83 'high SPZ1') showed distinct clinical features from the remaining HCC patients (n = 208; 'low SPZ1'). Comparison of the two groups and those without HCC showed significant differences in tumor size (P o 0.001), tumor number (P o 0.001), tumor grade (Po 0.001), lymphovascular invasion (P o0.01) and albumin concentration (P o0.05) ( Table 1 ). The patients in each group did not differ overall with regard to age, sex or the levels of alanine aminotransferase (ALT; glutamic-pyruvic transaminase), aspartate aminotransferase (AST; glutamic oxaloacetic transaminase), bilirubin, α-fetoprotein, AC sugar or cholesterol (Table 1 and Supplementary Table 1) . Compared with adjacent normal liver tissue, SPZ1 showed a tumor-specific expression pattern in HCC tumor masses (left) and was detected in both the cytoplasm and nuclei in tumor cells (right) (Figure 1b) . SPZ1 mRNA expression was significantly upregulated in HCC liver samples when compared with those from patients without HCC, as determined by a one-way ANOVA ( Figure 1a) . Analysis of the survival curves indicated that HCC patients with lower SPZ1 expression had a significantly longer survival than those with higher expression after hepatectomy ( Figure 1c , P o 0.001). These results suggested that SPZ1 may be involved in HCC progression and patient survival.
SPZ1 expression accelerates cell proliferation in hepatocellular carcinoma cell lines To study the potential oncogenic mechanism of SPZ1 in hepatoma cells, we surveyed the level of endogenous SPZ1 expression among various hepatoma cell lines. Analysis of six hepatoma cell lines showed that aggressive hepatoma cell lines, such as SK-Hep1 and HA 22T, expressed higher levels of SPZ1 expression than those of Hep G2 and Huh 7 hepatoma cells, while Alexander hepatoma cell line PLC5, Hep 3B and benign hepatocytes (Chang liver, CNL) had lower and undetectable levels of expression (Figure 1d Table 2 ). The SK-Hep1 hepatoma cells with high SPZ1 expression showed features of active proliferation compared with those showing no or low SPZ1 expression (Hep 3B and Huh 7 cells; Figure 1e) . A similar correlation between expression of SPZ1 and cell proliferation were also detected in other hepatoma cell lines (data not shown). We then used two different approaches, the forced expression and the knockdown of the SPZ1 gene, to investigate the role of SPZ1 in oncogenesis. Basically, we used the cell lines with higher endogenous expression of SPZ1 (for example, SK-Hep1) for analysis of the cellular activities in a series of the knockdown experiments; by contrast, we used the cell lines with lower endogenous expression of SPZ1 (for example, Hep G2 and Hep 3B) for the forced expression of SPZ1 and for validating the consequent cellular responses. In the knockdown experiments, we examined two different constructs, shRNAi1 and shRNAi2 and found both constructs reduced the expression of SPZ1 in SK-Hep1, HCC36 and Hep G2; however, in HA 22T, the reduction was not complete (Supplementary Figure S1a) . A similar correlation of cell proliferation were also detected in these hepatoma cell lines (Supplementary Figure S1b) . As expected, forced expression of SPZ1 significantly increased the levels of mRNA and protein of several genes related to proliferation, including cyclin D1, E2F1, and Ki67 in Hep G2 or Hep B3 hepatoma cells (Figures 1f and g ), but in the SK-Hep1 cells, while the knockdown of SPZ1 significantly repressed the expression of these cell cycle-related genes and ERK1/2 (Figure 1f and Supplementary Figure S1a and c) .
We next performed a cell cycle re-entry assay, counting bromodeoxyuridine (BrdU)-stained cells by flow cytometry (Figure 1h ). The percentage of G2/M cells in Flag-SPZ1-tranfected cells was higher than pFlag-transfected control cells (16.95 ± 1.88% vs 11.56 ± 0.13%). Thus, the forced expression of SPZ1 was able to enhance DNA synthesis and cell division in pFlag-SPZ1-Hep G2 cells compared with control pFlag transfected Hep G2 cells. In contrast, the knockdown construct SPZ1-shRNAi1 reduced the cell population at the G2/M phase as compared with that of control pLKO transfected cells (1.58 ± 0.25% vs 8.75 ± 0.26%), suggesting a role of SPZ1 in controlling cell cycle.
SPZ1 expression promotes tumorigenic activities in hepatoma cells
We then used the cell lines, SK-Hep1 and Huh 7, to confirm the activity of SPZ1 in promoting cell proliferation and tumorigenesis. SPZ1 functionally increased cell numbers and BrdU incorporation by promoting cell proliferation in the case of forced SPZ1-expressing cells, but the cell growth of SPZ1-knockdown cells (SPZ1 shRNAi1) was repressed as compared with that of mocktransfected hepatoma cells (Figures 2a and b) . Hepatoma cells overexpressing SPZ1-GFP showed increased transformation and oncogenic activity, whereas hepatoma cells with SPZ1-knockdown displayed decreased transformation and oncogenic abilities, as determined by soft agar anchorage-independent foci formation in vitro (Figure 2c ) and tumor growth in nude mice in vivo (Figure 2d ). Eighteen of sixty Spz1 transgenic mice developed tumors in each organ of 6-to 8-month transgenic mice; 15, 16 13 out of 60 transgenic mice developed hepatoma (Figure 2e ). These results suggested that SPZ1 plays an important role in promoting cell proliferation, transformation and oncogenicity in hepatoma cells.
SPZ1 transcriptionally activates human TWIST1 gene expression
We next examined the effect of SPZ1 on cell migration and invasion potency. In Hep G2 and Hep 3B cells, forced expression of SPZ1-GFP enhanced the expression of EMT markers, especially TWIST1, Snail1, Slug, Wnt5a, HIF-1, CD133, CD44, ZEB1 and BMI1 (Figure 3a and Supplementary Figure S2a ). Significant increases in the expression of EMT-related proteins were found, including Snail1, Slug, TWIST1, CD133, CD44 and moderately enhanced HIF-1 and Wnt5a; however, the expression of ZEB1 and BMI1 was not significantly altered. TWIST1 is the upstream key regulator of Snail1 and Slug to initiate the EMT process, 5, 17 the regulatory role of SPZ1 on TWIST1 expression and its functional outcomes was examined in SK-Hep1 and Huh 7 cell lines with doxycycline (DOX)-inducible SPZ1 expression constructs. As shown in Figures 3b and c, the expression of SPZ1 and TWIST1 was increased by DOX in a time-dependent manner (Figures 3b and c and Supplementary Figures S2b and S3d). These data suggested that SPZ1 was able to induce TWIST1 expression in hepatoma cells.
A series of deletion mutants of the TWIST1 promoter connected to a firefly luciferase reporter gene were constructed, and each mutant was assayed for luciferase activity in Hep G2 cells (Figure 3d ). A deletion of -230 to -249 bp in the construct reduced the luciferase activity by~10%. The DNA-binding activity of SPZ1 on the promoter region of TWIST1 was blocked when we deleted -230 to -249 bp relative to the transcriptional start site (Figure 3e) . Moreover, the transactivation activity induced by SPZ1 was also completely lost in the case of the deletion mutant (-230 to-249 bp; Figure 3f ). Interestingly, the guanine-rich sequence (Gbox) in the promoter of TWIST1 appeared to be the SPZ1-binding element in Hep G2, Huh 7, SK-Hep1 and HA 22T cells because the forced expression of pEGFP-SPZ1 increased the promoter activity of TWIST1, which was consistent with the ChIP assay data ( Figure 3g ). These results suggested that the TWIST1 promoter was transactivated by SPZ1 likely through a G-box element. 
Expression of SPZ1 significantly correlated with expression of TWIST1 in HCC patients
To examine the expression patterns of SPZ1 and TWIST1 in liver tumors, we found first that in Spz1-transgenic mice, liver tumor cells that overexpressed Spz1 (green) showed increased Twist1 expression (red), which was colocalized with Spz1 in the tumor mass ( Figure 4a ). In samples from patients with HCC, the high SPZ1 group showed higher expression of TWIST1 mRNA than the lower SPZ1 group (Figure 4b) . Also, SPZ1 mRNA expression correlated strongly with TWIST1 expression in patients with HCC (P o0.0001; Figure 4c ). In twelve randomly selected HCC samples obtained from patients with high SPZ1 expression, the increased SPZ1 expression correlated with TWIST1 expression, which was not observed in normal tissues adjacent to the tumor lesion (n = 291; Figure 4d and Supplementary Figure S3a) . The immunofluorescence staining of HCC samples showed the colocalized expression of both TWIST1 protein (red) and SPZ1 protein (green) in HCC cells (Figure 4e ). SPZ1-TWIST1 axis is important for the EMT activity of hepatoma cells To clarify the regulatory effects of the SPZ1-TWIST1 axis on the EMT, the markers of the EMT and cell migration were examined. SPZ1-or TWIST1-transfected Hep G2 and Hep 3B cells exhibited significantly increased mRNA and protein expression of mesenchymal markers (Snail, fibronectin and vimentin), but reduced levels of epithelial marker (E-cadherin) (Figure 5a and Supplementary Figure S3b) . Next, SK-Hep1 (with higher endogenous level of SPZ1 and TWIST1) transfected with either SPZ1 or TWIST1 shRNAi showed a significant increase in the mRNA and protein expression of the epithelial marker, E-cadherin, but decreased expression of the mesenchymal marker, N-cadherin. Further, the cells with double knockdown of SPZ1 and TWIST1 showed greater alteration of both the epithelial and mesenchymal markers (Figure 5b and Supplementary Figure S3c) . In the presence of TWIST1 shRNAi, the DOX induction of GFP-SPZ1 was found to reduce the expression of mesenchymal markers, such as Slug, Snail1, Fibronectin and N-cadherin, but not vimentin. Instead, the level of an epithelial marker, E-cadherin, returned to the original level ( Figure 5c ). Thus, these results indicated that SPZ1 may serve as the upstream regulator of TWIST1 for metastasis. In addition, Huh 7 cells transfected with either SPZ1 or TWIST1 exhibited increased cell mobility in a wound-healing assay and transwell invasion assay as compared with mock-transfected cells, whereas cotransfected cells with SPZ1 and TWIST1 exhibited higher wound-healing and invasion activities than those transfected with individual expression construct (Figures 5d and e, and Supplementary Figure 4a) . Further, SK-Hep1 with a double knockdown of SPZ1 and TWIST1 showed lower wound-healing and transwell invasion activities when compared with mock-transfected cells (Figures 5f and g ).
To moniter the tumor cell growth and dissemination in mice, SK-Hep1 cells stably expressing red fluorescent protein (RFP) were treated with an empty vector, SPZ1 shRNAi1 and/or TWIST1 shRNAi and were injected into nude mice. The tumor dissemination of SKHep1 cells depleted of SPZ1 or TWIST1 alone was inhibited, when compared with the dissemination of empty vector-transfected cells (Figure 5h ). Very few or no tumor cell signals (indicated as green or red dots) were detected in mice injected with SK-Hep1 cells with depletion of both SPZ1 and TWIST1 (Figure 5h ). These results suggested that the SPZ1-TWIST1 axis may play a role in promoting cell migration and invasion both in vitro and in vivo. More importantly, SPZ1 may serve as a critical upstream regulator of the TWIST1-dependent EMT cascade.
DISCUSSION
Here we report that SPZ1 activates the EMT inducer, TWIST1 and promotes oncogenic activity, leading to a poor prognosis and a poor clinical outcome in HCC. These findings provide the oncogenic and mechanistic evidence for the involvement of SPZ1 in tumorigenesis and suggest a newly recognized therapeutic target for liver cancer.
TWIST1 is a major regulator of mesodermal cell differentiation 3, 4 and promotes the malignant transformation in primary tumor formation and cell plasticity in the cellular microenvironment, and moreover promotes cancer cell stemness activity. 18 TWIST has been characterized by a highly conserved bHLH domain, and binds to E-box and G-box regulated target genes, resulting in the elaboration of an EMT transcriptional program. 3, 9, 10, 19, 20 Moreover, TWIST1 functions as a homodimer and heterodimers with E2A, HAND and other bHLH superfamily members.
2,21 During development, the TWIST1 dimer partner choice is, in part, regulated by the phosphorylation state of the Thr-Gln motif in helix1 of the TWIST1 protein, 21 and human mutations in TWIST1 that disrupt TWIST1 phosphorylation cause the autosomal dominant disease Saethre-Chotzen syndrome. 6, 22 These findings support a model where tight regulation of the phosphorylation state and dimeric partner choice of TWIST1 is essential for normal development. However, the upstream molecule that controls the TWIST1 expression, which is related to the cancer development that controls the TWIST1 expression has not yet been identified. Besides activation by the maternal Dorsal protein in Drosophila, the regulation of TWIST1 in tumor development remains still 3,4 Thus, to our knowledge, this is the first report to show a key upstream molecule controlling the EMT activity.
In mammals, two families, TWIST1 and TWIST2 share high structural homology. and TWIST2 lacks a glycine-rich region that is present in TWIST1.
19 TWIST1 has been identified as an inducer of EMT and a fundamental regulator of carcinoma metastasis. 23 However, the precise molecular mechanisms of TWIST1 in cancer progression have not been fully elucidated. TWIST1 promotes alteration of cells from the epithelial physiology to the mesenchymal phenotype, 8 and promotes prolonged TGFβ1-induced G2 arrest of cells, limiting the ability of the cells to repair and regenerate. 24 Moreover, TWIST1 expression is positively correlated with increased microvasculature in cancers, 20, 24 suggesting that TWIST1 can promote angiogenesis, possibly through upregulation of various biological factors such as MMP-2, -9 and VEGF. 25, 26 Thus, neovascularization induced by TWIST1 may facilitate the migration of cancer cells.
SPZ1 is regulated by RAS-ERK signaling pathways, which show classic characteristics of oncogenesis and promotion of cell proliferation in the early stage of expression, and then later, induced senescence and apoptosis in transgenic mice. 15, 16 Although the oncogenic and cell plasticity activity of SPZ1 remains unclear, SPZ1 overcame the oncogenic stress-induced oncosuppressive effect and led to tumor formation in transgenic mice. 16 In the present study, we showed that SPZ1 activated TWIST1 through promoter activation, and is a key molecule of EMT/MET activities during the metastatic stage of cancer. We found that SPZ1 exhibited expression activity that overlapped with that of TWIST1 in the embryo developmental stage, implying potential physiological regulatory effects between SPZ1 and TWIST1. SPZ1 was shown to activate and bind to the promoter of TWIST1 in an expression-dependent manner. TWIST1 is an upstream trigger of downstream Snail1 and Slug EMT marker genes. 5, 17, 27 Thus, SPZ1 is the initial target for triggering EMT and MET cascades. The upregulation of Snail1 and other CD133 and CD44 marker genes are transcriptionally regulated by SPZ1 (data not shown). The enhanced expression of CD133 and CD44 were found in cancer stem/progenitor cells population in hepatocellular carcinoma 28 and both CD133 + CD44 + tumor cells are a particular population of the cells responsible for metastasis of liver cancers cells. 29 This observation might be interesting and relevant because SPZ1 may control the expression of these markers, suggesting its candidacy as target for developing therapeutics for liver cancer.
We found that the chronic exposure to mitogens promoted the expression of SPZ1, and the enhanced expression of SPZ1 activated the mitogen-activated protein kinases (MAP kinase) cascade for cell proliferation and transformation in liver cells. 14 TWIST1 is also known to accelerate cell proliferation by deregulating cell cycle control through interacting with p300/CBP genetically to inhibit histone acetylation, 3, 8 or with epigenetic regulators to inhibit p53 function and activate PI3K/AKT signaling for oncogenesis. 11 Futher studies of signaling and epigenetic regulation of SPZ1-TWIST1 axis will be required to understand the role of SPZ1 in metastasis.
In summary, we show that SPZ1 promotes EMT transition by trans-activating the gene of TWIST1. A clinical analysis showed a marker association of SPZ1 and TWIST1 with induction of tumorigenesis in HCC patients. This SPZ1 is a diagnostic marker for a poor prognosis of HCC. The cascade of SPZ1 on TWIST1 activation is a prerequisite for EMT activation to initiate oncogenesis, and is a possible target for therapeutic treatment by new agents acting on the SPZ1 and TWIST1 axis.
MATERIALS AND METHODS
Patient samples
A total of 291 patients (220 men and 71 women; mean age: 58.3 ± 6.73; range: 25-82 years) with confirmed HCC, who had undergone curative used to confirm the identity of the original cell lines. Cells were grown in 90% Eagle Minimum Essential Medium (MEM; Gibco, Grand Island, NY, USA) with 2 mM L-glutamine and Earle's Balanced Salt Solution (BSS; Gibco) adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM nonessential amino acids (Gibco), 1.0 mM sodium pyruvate and 10% fetal bovine serum (Gibco). All cell lines have been routinely tested for mycoplasma contamination using a Universal Mycoplasma Detection Kit (Thermo Fisher Scientific, Waltham, MA, USA), and the last mycoplasma test was performed in December 2015. Mycoplasma-free cell lines were used in all experiments.
Plasmids
Full-length SPZ1 cDNA amplified from a human placenta cDNA library (Gibco-BRL, Grand Island, NY, USA) by PCR, was subcloned into a pEGFP/C1 vector (CloneTech, Mountain View, CA, USA) to express the GFP-tagged SPZ1 protein. Full-length TWIST1 cDNA was a gift from Dr Yang (National Yang-Ming Taiwan University, Taipei, Taiwan) and subcloned into a HAtagged pCDNA3.1 vectorb.
31 SPZ1-inducible systems in Huh 7 or SK-Hep1 cells were established by lentivirus infection as described elsewhere. 12 GFP-SPZ1 was subcloned into the pAS4W.puro vector (RNAi Core Center, Taipei, Taiwan) to establish a Tet-ON-inducible GFP-SPZ1 expression system. SPZ1 and TWIST1 shRNAi were constructed and subcloned into pLKO.puro (RNAi Core Center, Taipei, Taiwan). The shRNAi sequences of SPZ1 were as follows: shRNAi1 (nucleotide positions at 76-96); 5ʹ-GCTGTCTGAGATGCCACCTTC-3ʹ and shRNAi2 (nucleotide positions at 688-708); 5ʹ-AGAACTCTGAGAACACCGCAC-3ʹ. The shRNAi sequence of TWIST1 was showed as follows: TWIST1 shRNAi (nucleotide positions at 295-315); 5ʹ-AGTCCGCAGTCTTACGAG-3ʹ. Transfection was performed using the LipofectAMINE transfection kit (Gibco, Thermo Fisher Scientific, Waltham, MA, USA).
Western blotting and immunohistochemical staining analysis
Western blot analysis and immunohistochemical (fluorescence) staining were conducted as previously described. 14, 15 The primary antibodies used in this study were actin monoclonal antibody (1:5000, Merck, Darmstadt, Germany), E2F1 antibody (1:1000, Cell Signaling Technology, Beverly MA, USA), GFP monoclonal antibody (1:200, Upstate, Lake Placid, NY, USA), FITC-conjugated anti-rabbit, rhodamine-conjugated anti-mouse, alkaline phosphatase-conjugated anti-rabbit antibody (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA, USA), SPZ1, TWIST1, AKT, Ki67, HIF-1, Snail, Slug, Wnt5a, ZEB1, BMI1, fibronectin, E-cadherin rabbit polyclonal antibody (1:1000; GeneTex, Irvine, CA, USA). ERK1/2, PI3K monoclonal antibodies (Santa Cruz Biotechnology, Dallas, TX, USA). CD133, CD44, N-cadherin, vimentin rabbit polyclonal antibody (1:500, Abcam, Cambridge, MA, USA) All of the experiments were repeated at least three times.
Luciferase reporter assays
The TWIST1 promoter (between positions − 991 and +30) and its deletion mutant (between -230 and -249 bp) was cloned from human placental genomic DNA and was used to construct a pGL3 luciferase reporter plasmid. 32 The expression constructs and two reporter constructs, pSV40-Rluc and pGL3-TWIST1/Fire luciferase (Promega, Madison, WI, USA), were cotransfected with SPZ1 expression vector into 2 × 10 5 Hep 3B, SK-Hep1 and Huh 7 cells. The cells were collected 16 h after the transfection, and the relative luciferase activity was measured according to the manufacturer's instructions. All the data are expressed as the mean ± s.d. of at least three experiments.
Chromatin immunoprecipitation (ChIP) assays
The chromatin immunoprecipitation (ChIP) assays were performed as described previously. All the data are expressed as the mean ± s.d. of at least three experiments. TWIST1 promoter fragment was amplified with the following primers: primer 1, 5ʹ-TTGCCATTGCTGCTGTCAC-3ʹ; primer 2, 5ʹ-CGTCCTCCCAAACCATTCA-3ʹ.
Real-time PCR
The expressions of SPZ1 and TWIST1 mRNA in hepatoma cells and cells from cancer patients were quantified using the SYBR Green Quantitative RT-PCR kit (Invitrogen, Carlsbad, CA, USA) as described previously. The total RNA was extracted from the tumor mass using TRIzol reagent (Invitrogen) and then transcribed into cDNA (Invitrogen) for PCR amplification on a 7900HT Thermocycler (Applied Biosystems-Thermo Fisher Scientific, Walham, MA, USA ). All procedures and the data analysis were performed according to the manufacturers' instructions. All the data are expressed as the mean ± s.d. of at least three experiments.
Cell cycle analysis by flow cytometry Cell cycle phase analysis was performed using the FITC BrdU Flow Kit (BD Biosciences,San Jose, CA), according to the manufacturer's protocol. After treatment and BrdU labeling, cells were harvested and washed twice with PBS. To fix the cells, 0.7 ml of cold ethanol (70%) was added dropwise to a tube containing 0.3 ml of cell suspension in PBS and the cell suspension incubated on ice for 1 h. Subsequantly, the cells were washed twice with PBS and incubated with 100 μl of staining buffer contained 0.1 mg/ml propidium iodide, 2 mg/ml RNaseA and BrdU-FITC for 1 h at 37°C in the dark. The cells were then analyzed by flow cytometry (BD Bioscience, San Jose, CA, USA).
Anchorage-independent growth assays Cells (10 4 or 5 × 10
3 ) in 1 ml of a culture medium were mixed with an equal volume of 0.6% top agar and plated onto 60 mm culture dishes with 0.5% bottom agar. The plates were incubated at 37°C for 2 weeks. Colonies were visualized by staining with 0.05% crystal violet acetate, and only those larger than 0.5 mm were counted. The culture medium was replaced every 3 days. All the data are expressed as the mean ± s.d. of at least three experiments.
Preparation of transgenic mice and assessment of tumorigenic properties of SZP1 in nude mice Spz1 transgenic mice were established as described previously. 15, 16 In brief, a full-length Spz1 cDNA was subcloned into pCL-neo vector (Promega). A DNA fragment of pCMV-SpZ1 was gel-purified and introduced into RVB.N embryo pronuclei using microinjection procedures. Transgenic lines were identified by PCR using primers complementary to the vector sequences flanking the Spz1 gene: 5ʹ-CTTAAGGCTAGAGTACTTAA-3ʹ and 5ʹ-ATGTCTGCTCGAAGCATTAA-3ʹ. Six transgenic founders were obtained; lines T3 and T21, which had the highest Spz1 expression levels, were used in the following studies. Primary tumors of Spz1 transgenic mice were identified from 6-to 8-month-old mice. Male BALB/c nu/nu mice were inoculated (subcutaneous injection) with 10 6 of either scrambled vector or SPZ1 shRNAi1-transfected or overexpression cells on both sides of the back (10 mice per group). Tumor size was measured once or twice a week using a caliper. Tumor volume was estimated according to the formula: volume (cm 
Statistical analysis
The quantitative variables are presented as the mean ± s.d. The significance of differences was determined using a two-sample t test. Pearson's correlational and Mann-Whitney test analysis were used to examine the relationship between the levels of expression of SPZ1 and TWIST1. Statistical analysis of categorical variables was performed using chisquared analysis, one-way ANOVA and Fisher's exact analysis. Differences with a P o 0.05 were considered significant.
ABBREVIATIONS
bHLH, basic helix-loop helix; EMT, epithelial-mesenchymal transition; HCC, hepatocarcinoma cells; MET, mesenchymal-epithelial transition; SPZ1, spermatogenic leucine zipper 1.
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